Perspective Therapeutics Aktie

So dann mal auf in eine hoffentlich ereignisreiche und erfolgreiche Woche

Fast auf Tageshoch bei neuem 52Wochen Hoch geschlossen.
Stabil 💪

So langsam geht ‘r d’r Peeeter 🐿.

globalnewswire 11.3.24

Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024

SEATTLE, March 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will host an in-person and virtual analyst day at the New York Stock Exchange on Monday, March 18, 2024 at 10:00 AM ET. To register, click here.

The event will feature presentations from the following members of the Company’s management:

Thijs Spoor, Chief Executive Officer
Michael K. Schultz, PhD, Chief Science Officer
Markus Puhlman, MD, Chief Medical Officer
In addition, key opinion leader Richard L. Wahl, MD (Professor of Radiology, Mallinckrodt Institute of Radiology at Washington University School of Medicine) will provide an overview of the use of specialized targeting peptides and personalized alpha-particle radiopharmaceuticals such as 212Pb to diagnose tumors and deliver powerful radiation specifically to cancer cells.

The event will highlight the Company's theranostic approach and proprietary technology, including the development of complementary imaging diagnostics that enable the ability to see the specific tumor and then treat it, to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments. In addition, the Company’s management will discuss its next radiotherapy compound in development and provide an overview of its promising novel pretargeting technology.

A live question and answer session will follow the formal presentations.

About Richard L. Wahl, MD
Richard L. Wahl, MD, is a professor at Mallinckrodt Institute of Radiology (MIR) at Washington University School of Medicine in St. Louis and served as the director of MIR from 2014 to 2023. An alumnus, Wahl completed a diagnostic radiology residency and nuclear medicine fellowship at MIR. Prior to being named director at MIR, he was director of the Division of Nuclear Medicine at Johns Hopkins University and the first recipient of the Henry N. Wagner Jr. Professorship.

Wahl is a leader in the use of PET scans to diagnose human cancers and other diseases and was among the first to harness the power of the immune system to precisely target radiation therapy to cancers, a technique that has become known as radioimmunotherapy. He has been at the forefront of efforts to combine quantitative data from multiple kinds of scans to form so-called fusion images that can help physicians more precisely diagnose and characterize cancers.
Wahl has received numerous awards, including the 2018 Georg Charles de Hevesy Award from the Society of Nuclear Medicine and Molecular Imaging, where he served as president. He is an elected member of the American Society for Clinical Investigation, the American Association of Physicians and the National Academy of Medicine. A fellow of the American College of Radiology, Wahl holds 18 radiology patents and has published more than 450 peer-reviewed scientific manuscripts. He completed a research fellowship in immunology and earned his medical degree from Washington University in St. Louis.

Wäre doch mal ein schöner Wochenabschluss über 1,10$

Hier wächst ja nun augenscheinlich etwas und ich würde mir nun mal eine Meldung zu einem Auftrag aus dem Pharma oder Militärsektor wünschen. Die Möglichkeiten können mannigfaltiger beinahe nicht sein.

Globelnewswire
26.2.24


Perspective Therapeutics take part at Investor Conferences in Feb and March

SEATTLE, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that management will participate at upcoming discussions and investor conferences in February and March, 2024.
• Fireside Chat with JonesResearch – February 28, virtual
Time: 11 a.m. ET
Participant: Michael K. Schultz, Ph.D., Chief Science Officer

Please RSVP to your JonesResearch representative. Additional details will be provided upon registration.
• B. Riley Securities Inaugural Radiopharma Day – March 1, New York, NY


So dann schauen wir mal was unser CEO heute so bei Oppenheimer präsentiert und ob es interessierte Investoren gibt.